المؤلفون: Hardaker EL; Oncology R&D, AstraZeneca, Cambridge, UK., Sanseviero E; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Karmokar A; Oncology R&D, AstraZeneca, Cambridge, UK., Taylor D; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Milo M; Oncology R&D, AstraZeneca, Cambridge, UK., Michaloglou C; Oncology R&D, AstraZeneca, Cambridge, UK., Hughes A; Oncology R&D, AstraZeneca, Cambridge, UK., Mai M; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., King M; Oncology R&D, AstraZeneca, Cambridge, UK., Solanki A; Oncology R&D, AstraZeneca, Cambridge, UK., Magiera L; Oncology R&D, AstraZeneca, Cambridge, UK., Miragaia R; Oncology R&D, AstraZeneca, Cambridge, UK., Kar G; Oncology R&D, AstraZeneca, Cambridge, UK., Standifer N; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.; Tempest Therapeutics, Brisbane, CA, USA., Surace M; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Gill S; Oncology R&D, AstraZeneca, Cambridge, UK., Peter A; Oncology R&D, AstraZeneca, Cambridge, UK., Talbot S; Oncology R&D, AstraZeneca, Cambridge, UK., Tohumeken S; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Fryer H; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Mostafa A; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Mulgrew K; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Lam C; Oncology R&D, AstraZeneca, Cambridge, UK., Hoffmann S; Imaging and Data Analytics, AstraZeneca, Cambridge, UK., Sutton D; Imaging and Data Analytics, AstraZeneca, Cambridge, UK., Carnevalli L; Oncology R&D, AstraZeneca, Cambridge, UK., Calero-Nieto FJ; Oncology R&D, AstraZeneca, Cambridge, UK., Jones GN; Oncology R&D, AstraZeneca, Cambridge, UK., Pierce AJ; Oncology R&D, AstraZeneca, Cambridge, UK.; Crescendo Biologics Limited, Cambridge, UK., Wilson Z; Oncology R&D, AstraZeneca, Cambridge, UK., Campbell D; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Nyoni L; Oncology R&D, AstraZeneca, Cambridge, UK., Martins CP; Oncology R&D, AstraZeneca, Cambridge, UK., Baker T; CPSS AST, AstraZeneca, Cambridge, UK., Serrano de Almeida G; CPSS AST, AstraZeneca, Cambridge, UK., Ramlaoui Z; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Bidar A; CPSS, Imaging, AstraZeneca, Gothenburg, Sweden., Phillips B; Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Boland J; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Iyer S; Oncology R&D, AstraZeneca, Boston, MA, USA., Barrett JC; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Loembé AB; Early Clinical Development, AstraZeneca, Oss, the Netherlands., Fuchs SY; Department of Biomedical Sciences, School of Veterinary Medicine University of Pennsylvania, Philadelphia, PA, 19104, USA., Duvvuri U; UPMC Department of Otolaryngology and UPMC Hillman Cancer Center, 200 Lothrop St. Suite 500, Pittsburg, PA, 15213, USA., Lou PJ; National Taiwan University Hospital, No. 7, Chung Shan S. Rd. (Zhongshan S. Rd.), Zhongzheng Dist., Taipei City, 10002, Taiwan., Nance MA; VA Pittsburgh Healthcare System, University Drive C, Pittsburg, PA, 15240, USA., Gomez Roca CA; Institut Claudius Regaud-Cancer Comprehensive Center, 1 Avenue Irene Joliot-Curie, IUCT-O, Toulouse, 31059 Cedex 9, France., Cadogan E; Oncology R&D, AstraZeneca, Cambridge, UK., Critichlow SE; Oncology R&D, AstraZeneca, Cambridge, UK., Fawell S; Oncology R&D, AstraZeneca, Boston, MA, USA., Cobbold M; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Dean E; Oncology R&D, AstraZeneca, Cambridge, UK., Valge-Archer V; Oncology R&D, AstraZeneca, Cambridge, UK., Lau A; Oncology R&D, AstraZeneca, Cambridge, UK., Gabrilovich DI; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA. dmitry.gabrilovich@astrazeneca.com., Barry ST; Oncology R&D, AstraZeneca, Cambridge, UK. simon.t.barry@astrazeneca.com.

المصدر: Nature communications [Nat Commun] 2024 Feb 24; Vol. 15 (1), pp. 1700. Date of Electronic Publication: 2024 Feb 24.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

مواضيع طبية MeSH: CD8-Positive T-Lymphocytes* , Neoplasms* , Indoles* , Morpholines* , Pyrimidines* , Sulfonamides*, Humans ; Animals ; Mice ; B7-H1 Antigen ; Tumor Microenvironment ; Cell Line, Tumor ; Immunotherapy ; Disease Models, Animal ; Ataxia Telangiectasia Mutated Proteins

المؤلفون: Kwon M; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.; Department of Hematology-Oncology, Ajou University, Suwon, Republic of Korea., Kim G; Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea.; Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea., Kim R; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Kim KT; Department of Physiology, Ajou University, Suwon, Republic of Korea., Kim ST; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Smith S; Oncology R&D, AstraZeneca, Cambridge, UK., Mortimer PGS; Oncology R&D, AstraZeneca, Cambridge, UK., Hong JY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Loembé AB; Oncology R&D, AstraZeneca, Cambridge, UK., Irurzun-Arana I; Oncology R&D, AstraZeneca, Cambridge, UK., Koulai L; Oncology R&D, AstraZeneca, Cambridge, UK., Kim KM; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Kang WK; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Dean E; Oncology R&D, AstraZeneca, Cambridge, UK., Park WY; Samsung Genome Institute, Samsung Medical Center, Gangnam-gu, Republic of Korea., Lee J; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea jyunlee@skku.edu.; Department of Intelligent Precision Healthcare Convergence, Sungkyunkwan University, Suwon, Republic of Korea.

المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jul; Vol. 10 (7).

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal*/administration & dosage , Antibodies, Monoclonal*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Protein Kinase Inhibitors*/administration & dosage , Protein Kinase Inhibitors*/therapeutic use , Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/genetics , Stomach Neoplasms*/pathology, Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/therapeutic use ; Ataxia Telangiectasia Mutated Proteins/antagonists & inhibitors ; Ataxia Telangiectasia Mutated Proteins/genetics ; Humans ; Indoles/administration & dosage ; Indoles/therapeutic use ; Morpholines/administration & dosage ; Morpholines/therapeutic use ; Pyrimidines/administration & dosage ; Pyrimidines/therapeutic use ; Sulfonamides/administration & dosage ; Sulfonamides/therapeutic use ; Sulfoxides/administration & dosage ; Sulfoxides/therapeutic use

المؤلفون: Kim R; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Kwon M; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea., An M; Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea., Kim ST; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Smith SA; Oncology R&D, AstraZeneca, Cambridge, UK., Loembé AB; Oncology R&D, AstraZeneca, Cambridge, UK., Mortimer PGS; Oncology R&D, AstraZeneca, Cambridge, UK., Armenia J; Oncology R&D, AstraZeneca, Cambridge, UK., Lukashchuk N; Oncology R&D, AstraZeneca, Cambridge, UK., Shah N; Oncology R&D, AstraZeneca, Cambridge, UK., Dean E; Oncology R&D, AstraZeneca, Cambridge, UK., Park WY; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Geninus Inc., Seoul, Korea., Lee J; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Department of Intelligent Precision Healthcare Convergence, Sungkyunkwan University, Suwon, Korea. Electronic address: jyunlee@skku.edu.

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2022 Feb; Vol. 33 (2), pp. 193-203. Date of Electronic Publication: 2021 Oct 25.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Melanoma*/drug therapy , Melanoma*/genetics , Skin Neoplasms*/drug therapy, Antibodies, Monoclonal/adverse effects ; Humans ; Indoles ; Morpholines ; Pyrimidines ; Sulfonamides ; Tumor Microenvironment

المؤلفون: Kim ST; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea., Smith SA; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Mortimer P; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Loembé AB; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Cho H; Innovative Therapeutic Research Center, Precision Medicine Research Institute, Samsung Medical Center, Seoul, Korea., Kim KM; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Smith C; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Willis S; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Irurzun-Arana I; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Berges A; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Hong JY; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea., Park SH; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea., Park JO; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea., Park YS; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea., Lim HY; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea., Kang WK; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea., Kozarewa I; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Pierce AJ; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Dean E; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Lee J; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea. jyunlee@skku.edu.; Department of Intelligent Precision Healthcare Convergence, Sungkyunkwan University, Suwon, Korea.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Sep 01; Vol. 27 (17), pp. 4700-4709. Date of Electronic Publication: 2021 May 11.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents, Phytogenic/*administration & dosage , Indoles/*administration & dosage , Morpholines/*administration & dosage , Neoplasms/*drug therapy , Paclitaxel/*administration & dosage , Pyrimidines/*administration & dosage , Sulfonamides/*administration & dosage, Adult ; Aged ; Drug Administration Schedule ; Drug Combinations ; Female ; Humans ; Male ; Melanoma/drug therapy ; Middle Aged ; Skin Neoplasms/drug therapy

المؤلفون: Forster M; Department of Oncology, University College London Cancer Institute, London, UK; University College London Hospitals NHS Foundation Trust, London, UK., Hackshaw A; Cancer Research UK & UCL Cancer Trials Centre, University College London Cancer Institute, London, UK., De Pas T; Medical Oncology Department, Istituto Europeo di Oncologia, Milan, Italy., Cobo M; Medical Oncology Department, Hospital Universitario Málaga General FIMABIS, Málaga, Spain., Garrido P; Medical Oncology Department, University Hospital Ramón y Cajal, Madrid, Spain., Summers Y; Medical Oncology Department, Christie Hospital NHS Foundation Trust, Manchester, UK., Dingemans AC; Department of Pulmonology, Maastricht University Medical Center, Maastricht, The Netherlands., Flynn M; University College London Hospitals NHS Foundation Trust, London, UK., Schnell D; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., von Wangenheim U; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Loembé AB; Boehringer Ingelheim B.V., Alkmaar, The Netherlands., Kaiser R; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Institute of Pharmacology, University of Mainz, Mainz, Germany., Lee SM; Department of Oncology, University College London Cancer Institute, London, UK; University College London Hospitals NHS Foundation Trust, London, UK. Electronic address: smlee@ucl.ac.uk.

المصدر: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2018 Jun; Vol. 120, pp. 27-33. Date of Electronic Publication: 2018 Mar 09.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*drug therapy , Cisplatin/*therapeutic use , Deoxycytidine/*analogs & derivatives , Indoles/*therapeutic use , Lung Neoplasms/*drug therapy, Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/mortality ; Deoxycytidine/therapeutic use ; Disease-Free Survival ; Female ; Humans ; Lung Neoplasms/mortality ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Staging ; Prognosis ; Treatment Outcome ; Gemcitabine

المؤلفون: Palmer DH; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom. Daniel.Palmer@liverpool.ac.uk.; Clatterbridge Cancer Centre, Bebington, United Kingdom. Daniel.Palmer@liverpool.ac.uk., Ma YT; School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom., Peck-Radosavljevic M; Department of Gastroenterology & Hepatology, Medizinische Universität Wien, Vienna, Austria., Ross P; King's College Hospital NHS Foundation Trust, London, United Kingdom., Graham J; Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, United Kingdom., Fartoux L; Hôpital Saint-Antoine, Paris, France., Deptala A; Central Clinical Hospital of the Ministry of Interior, Department of Oncology and Hematology, Medical University of Warsaw, Warsaw, Poland., Studeny M; Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany., Schnell D; Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany., Hocke J; Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany., Loembé AB; Boehringer Ingelheim B.V., Alkmaar, The Netherlands., Meyer T; UCL Cancer Institute, University College London, London, United Kingdom.

المصدر: British journal of cancer [Br J Cancer] 2018 May; Vol. 118 (9), pp. 1162-1168. Date of Electronic Publication: 2018 Mar 22.

نوع المنشور: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Indoles*/administration & dosage , Indoles*/adverse effects , Indoles*/pharmacokinetics , Sorafenib*/administration & dosage , Sorafenib*/adverse effects , Sorafenib*/pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Hepatocellular/*drug therapy , Liver Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Carcinoma, Hepatocellular/epidemiology ; Carcinoma, Hepatocellular/metabolism ; Carcinoma, Hepatocellular/pathology ; Disease Progression ; Disease-Free Survival ; Europe/epidemiology ; Female ; Humans ; Liver Neoplasms/epidemiology ; Liver Neoplasms/metabolism ; Liver Neoplasms/pathology ; Male ; Maximum Tolerated Dose ; Middle Aged ; Treatment Outcome

المؤلفون: Yen CJ; Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Kim TY; Seoul National University Hospital, Seoul, Republic of Korea., Feng YH; Chi Mei Medical Center, Yongkang, Tainan, Taiwan., Chao Y; Taipei Veterans General Hospital, Taipei, Taiwan., Lin DY; Chang Gung Memorial Hospital & Chang Gung University, College of Medicine, Taoyuan, Taiwan., Ryoo BY; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Huang DC; Boehringer Ingelheim Taiwan Limited, Taipei, Taiwan., Schnell D; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany., Hocke J; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany., Loembé AB; Boehringer Ingelheim B.V., Alkmaar, the Netherlands., Cheng AL; National Taiwan University Hospital, Taipei, Taiwan.; National Taiwan University Cancer Center, Taipei, Taiwan.

المصدر: Liver cancer [Liver Cancer] 2018 May; Vol. 7 (2), pp. 165-178. Date of Electronic Publication: 2018 Mar 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: S. Karger Country of Publication: Switzerland NLM ID: 101597993 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2235-1795 (Print) Linking ISSN: 16645553 NLM ISO Abbreviation: Liver Cancer Subsets: PubMed not MEDLINE

المؤلفون: Grosso F; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Steele N; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Novello S; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Nowak AK; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Popat S; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Greillier L; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., John T; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Leighl NB; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Reck M; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Taylor P; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Planchard D; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Sørensen JB; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Socinski MA; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., von Wangenheim U; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Loembé AB; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Barrueco J; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Morsli N; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT., Scagliotti G; Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Nov 01; Vol. 35 (31), pp. 3591-3600. Date of Electronic Publication: 2017 Sep 11.

نوع المنشور: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Lung Neoplasms/*drug therapy , Mesothelioma/*drug therapy , Pleural Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Cisplatin/administration & dosage ; Disease-Free Survival ; Double-Blind Method ; Female ; Humans ; Indoles/administration & dosage ; Male ; Mesothelioma, Malignant ; Middle Aged ; Pemetrexed/administration & dosage

المؤلفون: Meyer T; UCL Cancer Institute, University College London, London, UK., Palmer DH; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.; Clatterbridge Cancer Centre, Bebington, UK., Cheng AL; National Taiwan University Hospital, Taipei, Taiwan., Hocke J; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Loembé AB; Boehringer Ingelheim B.V., Alkmaar, the Netherlands., Yen CJ; National Cheng Kung University Hospital, Tainan, Taiwan.

المصدر: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2017 Jul; Vol. 37 (7), pp. 1047-1055. Date of Electronic Publication: 2017 Feb 02.

نوع المنشور: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101160857 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1478-3231 (Electronic) Linking ISSN: 14783223 NLM ISO Abbreviation: Liver Int Subsets: MEDLINE

مواضيع طبية MeSH: Response Evaluation Criteria in Solid Tumors*, Antineoplastic Agents/*therapeutic use , Carcinoma, Hepatocellular/*drug therapy , Indoles/*therapeutic use , Liver Neoplasms/*drug therapy , Niacinamide/*analogs & derivatives , Phenylurea Compounds/*therapeutic use , Protein Kinase Inhibitors/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Carcinoma, Hepatocellular/diagnostic imaging ; Carcinoma, Hepatocellular/mortality ; Carcinoma, Hepatocellular/pathology ; Chi-Square Distribution ; Female ; Humans ; Indoles/adverse effects ; Kaplan-Meier Estimate ; Liver Neoplasms/diagnostic imaging ; Liver Neoplasms/mortality ; Liver Neoplasms/pathology ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Multivariate Analysis ; Niacinamide/adverse effects ; Niacinamide/therapeutic use ; Phenylurea Compounds/adverse effects ; Predictive Value of Tests ; Proportional Hazards Models ; Prospective Studies ; Protein Kinase Inhibitors/adverse effects ; Risk Factors ; Sorafenib ; Time Factors ; Tomography, X-Ray Computed

المؤلفون: Okusaka T; National Cancer Center Hospital, Tokyo, Japan., Otsuka T; Saga University Hospital, Saga, Japan., Ueno H; National Cancer Center Hospital, Tokyo, Japan., Mitsunaga S; National Cancer Center Hospital East, Kashiwa, Japan., Sugimoto R; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Muro K; Aichi Cancer Center Hospital, Nagoya, Japan., Saito I; Nippon Boehringer Ingelheim, Tokyo, Japan., Tadayasu Y; Nippon Boehringer Ingelheim, Kobe, Japan., Inoue K; EPS Corporation, Tokyo, Japan., Loembé AB; Boehringer Ingelheim, Alkmaar, The Netherlands., Ikeda M; National Cancer Center Hospital East, Kashiwa, Japan.

المصدر: Cancer science [Cancer Sci] 2016 Dec; Vol. 107 (12), pp. 1791-1799. Date of Electronic Publication: 2016 Dec 12.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study

بيانات الدورية: Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Carcinoma, Hepatocellular/*drug therapy , Carcinoma, Hepatocellular/*pathology , Indoles/*therapeutic use , Liver Neoplasms/*drug therapy , Liver Neoplasms/*pathology, Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Biomarkers, Tumor ; Carcinoma, Hepatocellular/complications ; Carcinoma, Hepatocellular/mortality ; Drug Monitoring ; Female ; Humans ; Indoles/administration & dosage ; Indoles/adverse effects ; Indoles/pharmacokinetics ; Liver Function Tests ; Liver Neoplasms/complications ; Liver Neoplasms/mortality ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Staging ; Treatment Outcome